Combination HRT patch versus estradiol-only patch: what is in the system?
A combination menopause patch contains estrogen plus a progestogen; an estradiol-only patch does not. FDA's October 20 announcement of an October 19 generic approval highlighted this distinction for women with an intact uterus, but the exact products are not interchangeable by appearance or schedule.
A combined menopause patch supplies estrogen and a progestogen in one product; an estradiol-only patch supplies estrogen without that second component. For someone with an intact uterus, the progestogen question is central to endometrial protection. On October 20, 2026, FDA announced that it had approved the first generic of the combined Climara Pro system on October 19 and contrasted it with estrogen-only patches. That approval does not make all combination patches the same or say the new generic is already available at every pharmacy.12
Count ingredients before comparing schedules
Climara is an estradiol-only patch. Climara Pro contains estradiol plus levonorgestrel; FDA’s new generic is therapeutically equivalent to that named combined reference product. CombiPatch is another combination product, but its progestogen is norethindrone acetate. The products also have their own labeling and wear instructions. “One patch instead of two medicines” may be attractive, but the active ingredients and the patient’s uterus status have to be understood first.123
| Box label | What it contains | Question it raises |
|---|---|---|
| Estradiol-only patch, e.g. Climara | Estradiol without a built-in progestogen. | If the uterus is present, what is the documented endometrial-protection plan? |
| Climara Pro or its named generic | Estradiol plus levonorgestrel in one weekly system. | Does the specific labeled combined product fit the person and indication? |
| CombiPatch | Estradiol plus norethindrone acetate. | Do not assume the same progestogen, wear schedule, or equivalence to Climara Pro. |
| A custom patch-plus-other-medicine regimen | Components prescribed separately. | Who tracks both prescriptions and the intended regimen? |
FDA says the progestogen in Climara Pro and its generic reduces the risk of endometrial hyperplasia that can occur with estrogen alone in women with an intact uterus. This is a product-specific rationale, not an assurance that the combined patch has no other risks. FDA lists significant contraindications and adverse reactions in its announcement; a prescribing clinician must review the exact label and the person’s history.1
A generic approval has a narrow meaning
The October 20 news announced FDA’s October 19 approval of the first generic of Climara Pro. It is not an FDA announcement that all HRT patches are equivalent, that a combination patch is always preferable, or that prices and stock have changed locally. Ask a pharmacy or prescriber about the exact approved product if access matters. Do not infer a Florida price or availability from the approval notice.1
This is also different from patch versus pill, a route comparison. Both products in the present comparison are patches. The decision turns on what hormones are in the patch, whether a uterus is present, and whether the label and follow-up plan fit. The continuous-versus-cyclic guide handles a separate regimen-pattern question.
A clean prescription conversation
The FDA’s generic announcement adds a useful access question, but an approval is not a stock notice or a personal cost estimate. If the new estradiol/levonorgestrel generic is offered, the prescriber can confirm the exact reference product and the pharmacist can clarify substitution and supply. A different combination patch such as CombiPatch is not automatically a substitute for Climara Pro merely because it also contains two hormones. Its progestogen is different, and the regimen may be different as well.13
Be careful with the phrase “progesterone patch.” Many combination menopause patches contain a progestin, not the natural progesterone molecule. The package’s ingredient list is more reliable than a menu label. This distinction does not make one product better by default; it prevents a person from believing a named hormone is included when it is not. A clinician can explain why a particular progestogen and route were chosen.
Bring a complete medication list and ask the prescriber to point to each active ingredient on the proposed package. Then ask: “If my uterus is present, how is endometrial protection addressed? If it is not, why choose this product? What change in bleeding should I report, and who handles a refill or substitution?” A patch’s familiar shape does not tell the patient the answer.
Use Treomark’s hormone-therapy hub to compare ongoing-care access. Ask for an exact product and written plan; avoid treating “combined” as a quality rating or “estradiol only” as an automatically incomplete prescription without knowing the patient’s anatomy and care context.
Sources
- U.S. Food and Drug Administration. FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women. October 20, 2026 announcement of the October 19 first-generic approval for Climara Pro, its two active ingredients, intended intact-uterus use, and therapeutic equivalence to the named reference product. Accessed .
- National Library of Medicine DailyMed. CLIMARA estradiol patch prescribing information. An estradiol-only patch example, including endometrial-risk language. Accessed .
- National Library of Medicine DailyMed. COMBIPATCH estradiol/norethindrone acetate patch prescribing information. A different combination product, demonstrating why ingredient and schedule must be read from the exact label. Accessed .